



Fund Details

Investment Objective

The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes' objectives will be achieved.

Fund Manager

Mr. Dhaval Shah & Mr. Dhaval Joshi

Date of Allotment

July 11, 2019

Benchmark

S&P BSE Healthcare TRI

Managing Fund Since

July 11, 2019 & November 21, 2022

Experience in Managing the Fund

4.1 Years & 0.7 Years

SIP

Monthly: Minimum ₹ 500/-

Fund Category

Thematic (Equity)

Investment Style

| | | | |
|-----------|--------|-------|-------|
| Large Cap | | | |
| Mid Cap | | | |
| Small Cap | | | |
| | Growth | Value | Blend |

Load Structure (as % of NAV) (Incl. for SIP)

| | |
|------------|---|
| Entry Load | Nil |
| Exit Load | For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil |

AUM

| | | | |
|---------------------|---|--------|--------|
| Monthly Average AUM | ₹ | 500.14 | Crores |
| AUM as on last day | ₹ | 523.47 | Crores |

Total Expense Ratio (TER)

| | |
|---|-------|
| Regular | 2.44% |
| Direct | 1.09% |
| Including additional expenses and goods and service tax on management fees. | |



INVEST NOW

Other Parameters

| | |
|--------------------|--------|
| Standard Deviation | 15.03% |
| Sharpe Ratio | 0.50 |
| Beta | 0.94 |
| Portfolio Turnover | 0.38 |

Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 6.6% (FBIL Overnight MIBOR as on 31 July 2023) for calculating Sharpe Ratio

Application Amount for fresh subscription

₹ 1,000 (plus in multiples of ₹ 1)

Min. Addl. Investment

₹ 1,000 (plus in multiples of ₹ 1)

PORTFOLIO

| Issuer | % to Net Assets | Rating |
|--|-----------------|--------|
| Pharmaceuticals & Biotechnology | 79.75% | |
| Sun Pharmaceutical Industries Limited | 14.45% | |
| Cipla Limited | 7.15% | |
| Torrent Pharmaceuticals Limited | 6.76% | |
| Aurobindo Pharma Limited | 6.60% | |
| Dr. Reddys Laboratories Limited | 4.67% | |
| Zydus Lifesciences Limited | 4.20% | |
| Lupin Limited | 3.81% | |
| Alkem Laboratories Limited | 3.70% | |
| J.B. Chemicals & Pharmaceuticals Limited | 2.94% | |
| Biocon Limited | 2.94% | |
| Abbott India Limited | 2.38% | |
| ALEMBIC PHARMACEUTICALS LIMITED | 2.38% | |
| Strides Pharma Science Limited | 2.32% | |
| Ajanta Pharmaceuticals Limited | 2.32% | |
| Gland Pharma Limited | 2.32% | |
| Natco Pharma Limited | 2.28% | |
| Sanofi India Limited | 2.24% | |

| Issuer | % to Net Assets | Rating |
|---------------------------------------|-----------------|--------|
| Mankind Pharma Ltd | 2.16% | |
| Eris Lifesciences Limited | 2.14% | |
| Granules India Limited | 1.01% | |
| Indoco Remedies Limited | 1.01% | |
| Healthcare Services | 15.72% | |
| Apollo Hospitals Enterprise Limited | 7.31% | |
| Fortis Healthcare Limited | 4.81% | |
| Global Health Ltd/India | 1.29% | |
| Vijaya Diagnostic Centre Limited | 1.24% | |
| Syngene International Limited | 1.08% | |
| Chemicals & Petrochemicals | 1.30% | |
| Vinati Organics Limited | 1.30% | |
| Retailing | 1.22% | |
| Medplus Health Services Limited | 1.22% | |
| Food Products | 0.82% | |
| Zydus Wellness Limited | 0.82% | |
| Cash & Current Assets | 1.18% | |
| Total Net Assets | 100.00% | |



Investment Performance

NAV as on July 31, 2023: ₹ 20.6100

| Inception - July 11, 2019 | Since Inception | 5 Years | 3 Years | 1 Year |
|--|-----------------|---------|---------|--------|
| Aditya Birla Sun Life Pharma & Healthcare Fund | 19.50% | NA | 14.11% | 20.40% |
| Value of Std Investment of ₹ 10,000 | 20,610 | NA | 14,859 | 12,053 |
| Benchmark - S&P BSE Healthcare TRI | 22.04% | NA | 15.66% | 22.04% |
| Value of Std Investment of ₹ 10,000 | 22,454 | NA | 15,470 | 12,217 |
| Additional Benchmark - Nifty 50 TRI | 15.62% | NA | 22.71% | 16.18% |
| Value of Std Investment of ₹ 10,000 | 18,029 | NA | 18,479 | 11,628 |

Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 5. Total Schemes managed by Mr. Dhaval Joshi is 45. Refer annexure on page no. 164-165 to know more on performance of schemes managed by Fund Managers.

Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.



NAV of Plans / Options (₹)

| | Regular Plan | Direct Plan |
|---------------|--------------|-------------|
| Growth | 20.6100 | 22.0400 |
| IDCW* | 16.4900 | 17.6400 |

*Income Distribution cum capital withdrawal



SIP Performance - Regular Plan - Growth (assuming SIP of ₹ 10000 per month)

| Particulars | Since Inception | 5 years | 3 years | 1 Year |
|---------------------------------|-----------------|---------|---------|--------|
| Total Amount Invested (₹) | 490000 | NA | 360000 | 120000 |
| Market Value of amount Invested | 681297 | NA | 433237 | 143551 |
| Scheme Returns (CAGR) | 16.30% | NA | 12.43% | 38.50% |
| S&P BSE Healthcare TRI# (CAGR) | 18.77% | NA | 13.79% | 39.44% |
| Nifty 50 TRI## (CAGR) | 18.23% | NA | 16.41% | 20.90% |

Date of First Installment: August 01, 2019 & Scheme Inception Date: July 11, 2019. Past Performance may or may not be sustained in future.

Scheme Benchmark, ## Additional Benchmark

For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return). Where Benchmark returns are not available, they have not been shown. **Past performance may or may not be sustained in future.** Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.